产品名称 |
OCI-LY1 B细胞淋巴瘤 |
货号 |
ZQ1067 |
产品介绍 |
源自一名 44 岁男性 B 细胞非霍奇金淋巴瘤(B-NHL;弥漫性大细胞)的骨髓,1983 年复发时处于 4B 期;分配给 GCB 样淋巴瘤亚型(生发中心 B 细胞)。OCI-LY1细胞系在弥漫大B细胞淋巴瘤(DLBCL)的研究中被广泛使用,包括药物筛选、病理机制研究以及免疫治疗的研究。例如,在研究中,OCI-LY1细胞被用来评估来那度胺对DLBCL细胞的体外杀伤效力,以及与第三代CD19 CAR-T细胞联合治疗DLBCL的效果。 |
种属 |
人 |
性别/年龄 |
男/44岁 |
组织 |
骨髓 |
疾病 |
大B细胞淋巴瘤 |
细胞类型 |
肿瘤细胞 |
形态学 |
小圆至多形细胞在悬浮液中单独生长 |
生长方式 |
悬浮 |
倍增时间 |
~50-60 hours (DSMZ=ACC-722) |
培养基和添加剂 |
RPMI-1640(中乔新舟 货号:ZQ-200)+20%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
ZM1067 |
生物安全等级 |
BSL-1 |
培养条件 |
95%空气,5%二氧化碳;37℃ |
STR位点信息 |
Amelogenin :X,Y CSF1PO: 10,11 D2S1338 :21,24 D3S1358 :16,17 D5S818: 11,12 D7S820: 11 D8S1179: 8,15 D13S317: 12 D16S539: 9 D18S51 :12 D19S433 :13,15 D21S11 :29,30 FGA :21,22 Penta D: 9,11 Penta E: 7,10 TH01 :9.3 TPOX :8,9 vWA :15,16 |
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
DSMZ; ACC-722 |
供应限制 |
仅供科研使用 |
货号 |
ZQ1067 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307
Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R., Lockwood G., Minden M.D., Messner H.A.
The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor.
Blood 69:1307-1314(1987)
PubMed=8574164; DOI=10.3109/10428199509059672
Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Leuk. Lymphoma 19:165-171(1995)
PubMed=10676951; DOI=10.1038/35000501
Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L.-M., Marti G.E., Moore T., Hudson J. Jr., Lu L.-S., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R.A., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature 403:503-511(2000)
PubMed=11807979; DOI=10.1002/gcc.10025
Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.
Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.
Genes Chromosomes Cancer 33:225-234(2002)
PubMed=12169673; DOI=10.1016/S1525-1578(10)60693-9
Robetorye R.S., Bohling S.D., Morgan J.W., Fillmore G.C., Lim M.S., Elenitoba-Johnson K.S.J.
Microarray analysis of B-cell lymphoma cell lines with the t(14;18).
J. Mol. Diagn. 4:123-136(2002)
PubMed=19278952; DOI=10.1182/blood-2009-01-202028
Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Blood 113:6681-6690(2009)
PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)
PubMed=20628145; DOI=10.1182/blood-2010-05-282780
Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., Kutok J.L., Shipp M.A.
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Blood 116:3268-3277(2010)
PubMed=23257783; DOI=10.1038/leu.2012.367
Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Leukemia 27:1381-1390(2013)
PubMed=23292937; DOI=10.1073/pnas.1205299110
Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)
PubMed=23699601; DOI=10.1182/blood-2013-02-483727
Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R., Huff R.D., Scott D.W., Ding J.-R., Roth A., Chiu R., Corbett R.D., Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G., Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B.W., Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S.P., Jones S.J.M., Steidl C., Holt R.A., Birol I., Moore R., Connors J.M., Gascoyne R.D., Marra M.A.
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Blood 122:1256-1265(2013)
PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)